Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 17INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 2Genitourinary 1

Conditions

Disease 2Brain Neoplasms 2Prostatic Neoplasms 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × fluciclovine F-18 × Clear all
NCT04410133 2025-08-28

REVELATE

Blue Earth Diagnostics

Phase 3 Completed
151 enrolled 29 charts
CNS

Brain Neoplasms, Disease

NCT04410367 2025-07-20

PURSUE

Blue Earth Diagnostics

Phase 2 Completed
23 enrolled 10 charts
CNS

Brain Neoplasms, Disease

NCT02443571 2018-12-19

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

Blue Earth Diagnostics

Completed
714 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡